English
ibudilast
Sign in to saveAlso known as AV-411, KC-404, Ketas®, MN-166, Ibudilastum
Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.
Research
304 papers- Ibudilast for the treatment of multiple sclerosis.Expert opinion on investigational drugs · 2016
- Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?Neurology · 2021
- Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.Brain : a journal of neurology · 2023
- Ibudilast: a non‑selective phosphodiesterase inhibitor in brain disorders.Postepy higieny i medycyny doswiadczalnej (Online) · 2017
- Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024
via PubMed
~2 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Pharmacology
- Pharmacodynamics
- References
Ibudilast (development codes: AV-411 or MN-166) is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.
==Medical uses== In Japan, ibudilast oral capsules are approved for the treatment of asthma, and for improvement of dizziness secondary to chronic cerebral circulation impairment associated with sequelae of cerebral infarction. Ibudilast ophthalmic solution is indicated for the treatment of allergic conjunctivitis and hay fever.
Excerpted from Wikipedia’s “ibudilast” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0